Exploring bi-directional impacts of Lisdexamfetamine dimesylate on psychological comorbidities and quality of life in people with Binge Eating Disorder.
ADHD
Anxiety
Depression
Medication
Mental Health
Pharmacotherapy
Psychopharmacology
Journal
Journal of eating disorders
ISSN: 2050-2974
Titre abrégé: J Eat Disord
Pays: England
ID NLM: 101610672
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
29
02
2024
accepted:
05
06
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
13
6
2024
Statut:
epublish
Résumé
Lisdexamfetamine dimesylate (LDX) has demonstrated safety and efficacy for treatment of Binge Eating Disorder (BED). However, to date, trials have not included participants with co-occurring psychiatric disorders. This study explores how LDX affects eating disorder psychopathology, symptoms of common psychiatric comorbidities of BED (ADHD, depression, anxiety), and psychological quality of life, in people with moderate to severe BED. These are secondary analyses of an open-label LDX trial conducted in 41 adults (18-40 years) over eight-weeks. Participants received LDX titrated to 50 or 70 mg. Clinical assessments and self-report questionnaires were conducted at baseline and 8-week follow-up. Eating disorder psychopathology and psychological quality of life improved after 8-weeks of LDX. No significant group-level changes in depression, anxiety or ADHD severity scores were observed. However, the majority within the small subsets with elevated depression and ADHD symptoms experienced reduced depressive and inattentive symptom severity, respectively. We provide proof-of-concept evidence that LDX may provide broader psychological benefits to individuals with BED, beyond reducing their BE frequency. Effects of LDX on anxiety should be monitored closely by clinicians. Early indications suggest that LDX may be effectively used in people with BED, with and without co-occurring psychiatric conditions, however tolerability may be lower in highly complex cases. Australian and New Zealand Clinical Trials Registry (anzctr.org.au) #ACTRN12618000623291. Lisdexamfetamine dimesylate (LDX) has been shown to reduce binge eating frequency among those with Binge Eating Disorder (BED). However, little is known about how LDX affects symptoms of common co-occurring conditions (ADHD, depression, anxiety) and mental health more broadly. In this study, 41 people with BED received an 8-week course of LDX and their symptoms were monitored before and after treatment. Overall, people experienced a robust improvement in eating disorder psychopathology and psychological quality of life. For those with higher levels of depression and ADHD, LDX had the additional benefit of improving depressive symptoms and inattentive symptom severity, respectively. The effect of LDX on anxiety symptoms appears to be more complex, with an equal proportion of people experiencing a decrease or an increase in anxiety over the course of treatment. Those who experienced reductions in anxiety during treatment tended to have greater concurrent reductions in binge eating frequency. This study provides preliminary evidence that for people with BED, LDX may be effective at improving co-occurring symptoms of eating disorder psychopathology and psychological well-being, and potentially ADHD and depression symptoms when present at an elevated level. More research is needed among a larger sample to verify these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Lisdexamfetamine dimesylate (LDX) has demonstrated safety and efficacy for treatment of Binge Eating Disorder (BED). However, to date, trials have not included participants with co-occurring psychiatric disorders. This study explores how LDX affects eating disorder psychopathology, symptoms of common psychiatric comorbidities of BED (ADHD, depression, anxiety), and psychological quality of life, in people with moderate to severe BED.
METHODS
METHODS
These are secondary analyses of an open-label LDX trial conducted in 41 adults (18-40 years) over eight-weeks. Participants received LDX titrated to 50 or 70 mg. Clinical assessments and self-report questionnaires were conducted at baseline and 8-week follow-up.
RESULTS
RESULTS
Eating disorder psychopathology and psychological quality of life improved after 8-weeks of LDX. No significant group-level changes in depression, anxiety or ADHD severity scores were observed. However, the majority within the small subsets with elevated depression and ADHD symptoms experienced reduced depressive and inattentive symptom severity, respectively.
CONCLUSIONS
CONCLUSIONS
We provide proof-of-concept evidence that LDX may provide broader psychological benefits to individuals with BED, beyond reducing their BE frequency. Effects of LDX on anxiety should be monitored closely by clinicians. Early indications suggest that LDX may be effectively used in people with BED, with and without co-occurring psychiatric conditions, however tolerability may be lower in highly complex cases.
TRIAL REGISTRATION
BACKGROUND
Australian and New Zealand Clinical Trials Registry (anzctr.org.au) #ACTRN12618000623291.
Lisdexamfetamine dimesylate (LDX) has been shown to reduce binge eating frequency among those with Binge Eating Disorder (BED). However, little is known about how LDX affects symptoms of common co-occurring conditions (ADHD, depression, anxiety) and mental health more broadly. In this study, 41 people with BED received an 8-week course of LDX and their symptoms were monitored before and after treatment. Overall, people experienced a robust improvement in eating disorder psychopathology and psychological quality of life. For those with higher levels of depression and ADHD, LDX had the additional benefit of improving depressive symptoms and inattentive symptom severity, respectively. The effect of LDX on anxiety symptoms appears to be more complex, with an equal proportion of people experiencing a decrease or an increase in anxiety over the course of treatment. Those who experienced reductions in anxiety during treatment tended to have greater concurrent reductions in binge eating frequency. This study provides preliminary evidence that for people with BED, LDX may be effective at improving co-occurring symptoms of eating disorder psychopathology and psychological well-being, and potentially ADHD and depression symptoms when present at an elevated level. More research is needed among a larger sample to verify these findings.
Autres résumés
Type: plain-language-summary
(eng)
Lisdexamfetamine dimesylate (LDX) has been shown to reduce binge eating frequency among those with Binge Eating Disorder (BED). However, little is known about how LDX affects symptoms of common co-occurring conditions (ADHD, depression, anxiety) and mental health more broadly. In this study, 41 people with BED received an 8-week course of LDX and their symptoms were monitored before and after treatment. Overall, people experienced a robust improvement in eating disorder psychopathology and psychological quality of life. For those with higher levels of depression and ADHD, LDX had the additional benefit of improving depressive symptoms and inattentive symptom severity, respectively. The effect of LDX on anxiety symptoms appears to be more complex, with an equal proportion of people experiencing a decrease or an increase in anxiety over the course of treatment. Those who experienced reductions in anxiety during treatment tended to have greater concurrent reductions in binge eating frequency. This study provides preliminary evidence that for people with BED, LDX may be effective at improving co-occurring symptoms of eating disorder psychopathology and psychological well-being, and potentially ADHD and depression symptoms when present at an elevated level. More research is needed among a larger sample to verify these findings.
Identifiants
pubmed: 38872181
doi: 10.1186/s40337-024-01041-9
pii: 10.1186/s40337-024-01041-9
doi:
Banques de données
ANZCTR
['ACTRN12618000623291']
Types de publication
Journal Article
Langues
eng
Pagination
80Subventions
Organisme : NHMRC Early Career Fellowship
ID : GNT1122842
Organisme : Takeda Pharmaceutical Australia Pty Ltd
ID : IISR-2017-104128/IIR-AUS-001429
Informations de copyright
© 2024. The Author(s).
Références
Santomauro DF, Melen S, Mitchison D, Vos T, Whiteford H, Ferrari AJ. The hidden burden of eating disorders: an extension of estimates from the Global Burden of Disease Study 2019. Lancet Psychiatry. 2021;8(4):320–8.
doi: 10.1016/S2215-0366(21)00040-7
pubmed: 33675688
pmcid: 7973414
Galmiche M, Déchelotte P, Lambert G, Tavolacci MP. Prevalence of eating disorders over the 2000–2018 period: a systematic literature review. Am J Clin Nutr. 2019;109(5):1402–13.
doi: 10.1093/ajcn/nqy342
pubmed: 31051507
Udo T, Grilo CM. Psychiatric and medical correlates of DSM-5 eating disorders in a nationally representative sample of adults in the United States. Int J Eat Disord. 2019;52(1):42–50.
doi: 10.1002/eat.23004
pubmed: 30756422
Nazar BP, Bernardes C, Peachey G, Sergeant J, Mattos P, Treasure J. The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Int J Eat Disord. 2016;49(12):1045–57.
doi: 10.1002/eat.22643
pubmed: 27859581
Hambleton A, Pepin G, Le A, Maloney D, Touyz S, Maguire S. Psychiatric and medical comorbidities of eating disorders: findings from a rapid review of the literature. J Eat Disord. 2022;10(1):132.
doi: 10.1186/s40337-022-00654-2
pubmed: 36064606
pmcid: 9442924
McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(3):235–46. https://doi.org/10.1001/jamapsychiatry.2014.2162 .
doi: 10.1001/jamapsychiatry.2014.2162
McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251–60.
doi: 10.1038/npp.2015.275
pubmed: 26346638
Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017;37(3):315.
doi: 10.1097/JCP.0000000000000702
pubmed: 28383364
pmcid: 5400413
Fornaro M, Solmi M, Perna G, et al. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatr Dis Treat. 2016;12:1827–36. https://doi.org/10.2147/ndt.S109637 .
doi: 10.2147/ndt.S109637
pubmed: 27524900
pmcid: 4966690
Griffiths KR, Aparício L, Braund TA, et al. Impulsivity and its relationship with lisdexamfetamine dimesylate treatment in binge eating disorder. Front Psychol. 2021;12:716010.
doi: 10.3389/fpsyg.2021.716010
pubmed: 34531798
pmcid: 8439192
McElroy SL, Mitchell JE, Wilfley D, et al. Lisdexamfetamine dimesylate effects on binge eating behaviour and obsessive-compulsive and impulsive features in adults with binge eating disorder. Eur Eat Disord Rev. 2016;24(3):223–31. https://doi.org/10.1002/erv.2418 .
doi: 10.1002/erv.2418
pubmed: 26621156
Schneider E, Martin E, Rotshtein P, et al. The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study. Transl Psychiatry. 2022;12(1):1–8.
doi: 10.1038/s41398-021-01770-4
Cortese S, Bernardina BD, Mouren M-C. Attention-deficit/hyperactivity disorder (ADHD) and binge eating. Nutr Rev. 2007;65(9):404–11.
doi: 10.1111/j.1753-4887.2007.tb00318.x
pubmed: 17958207
Giacobbe P, Rakita U, Lam R, Milev R, Kennedy SH, McIntyre RS. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: a meta-analysis of randomized controlled trials. J Affect Disord. 2018;226:294–300.
doi: 10.1016/j.jad.2017.09.041
pubmed: 29028590
Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2017;74(9):903–10.
doi: 10.1001/jamapsychiatry.2017.1889
Griffiths KR, Yang J, Touyz SW, et al. Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol. J Eat Disord. 2019;7:23. https://doi.org/10.1186/s40337-019-0253-3 .
doi: 10.1186/s40337-019-0253-3
pubmed: 31333843
pmcid: 6621979
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28.
pubmed: 20526405
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22–33.
pubmed: 9881538
Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994;16(4):363–70.
doi: 10.1002/1098-108X(199412)16:4<363::AID-EAT2260160405>3.0.CO;2-#
pubmed: 7866415
Mond JM, Hay PJ, Rodgers B, Owen C, Beumont PJ. Validity of the Eating Disorder Examination Questionnaire (EDE-Q) in screening for eating disorders in community samples. Behav Res Ther. 2004;42(5):551–67.
doi: 10.1016/S0005-7967(03)00161-X
pubmed: 15033501
Berg KC, Peterson CB, Frazier P, Crow SJ. Psychometric evaluation of the eating disorder examination and eating disorder examination-questionnaire: a systematic review of the literature. Int J Eat Disord. 2012;45(3):428–38.
doi: 10.1002/eat.20931
pubmed: 21744375
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56.
doi: 10.1136/jnnp.23.1.56
pubmed: 14399272
pmcid: 495331
Trajković G, Starčević V, Latas M, et al. Reliability of the Hamilton Rating Scale for Depression: a meta-analysis over a period of 49 years. Psychiatry Res. 2011;189(1):1–9.
doi: 10.1016/j.psychres.2010.12.007
pubmed: 21276619
Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013;150(2):384–8.
doi: 10.1016/j.jad.2013.04.028
pubmed: 23759278
Hamilton M. The assessment of anxiety states by rating. British journal of medical psychology. 1959
Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61–8.
doi: 10.1016/0165-0327(88)90072-9
pubmed: 2963053
Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–56.
doi: 10.1017/S0033291704002892
pubmed: 15841682
Stanton K, Forbes MK, Zimmerman M. Distinct dimensions defining the adult ADHD self-report scale: implications for assessing inattentive and hyperactive/impulsive symptoms. Psychol Assess. 2018;30(12):1549.
doi: 10.1037/pas0000604
pubmed: 29878817
Adler LA, Spencer T, Faraone SV, et al. Validity of pilot Adult ADHD self-report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry. 2006;18(3):145–8.
doi: 10.1080/10401230600801077
pubmed: 16923651
Group W. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551–8.
doi: 10.1017/S0033291798006667
Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.
doi: 10.1023/B:QURE.0000018486.91360.00
pubmed: 15085902
Aiken LS, West SG, Reno RR. Multiple regression: testing and interpreting interactions. London: Sage; 1991.
Team RC. R: a language and environment for statistical computing (3.5.1.) [Computer software]. Vienna: R Foundation for Statistical Computing; 2020.
Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. 67, 48. arXiv preprint arXiv:14065823. 2015;
Kuznetsova A, Brockhoff PB, Christensen RH. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82(13):1–26.
doi: 10.18637/jss.v082.i13
Lenth R, Singmann H, Love J, Buerkner P. emmeans: estimated marginal means, aka least-squares means. R package. 2019;1(3):4.
Najib J, Wimer D, Zeng J, et al. Review of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Cent Nerv Syst Dis. 2017;9:1179573517728090.
doi: 10.1177/1179573517728090
pubmed: 28855799
pmcid: 5571766
Rosenbaum DL, White KS. The role of anxiety in binge eating behavior: a critical examination of theory and empirical literature. Health Psychol Res. 2013;1(2):e19.
doi: 10.4081/hpr.2013.714
pubmed: 26973904
pmcid: 4768578
Soul S, et al. Stimulant treatment effect on anxiety domains in children with attention-deficit/hyperactivity disorder with and without anxiety disorders: a 12-week open-label prospective study. J Child Adolesc Psychopharmacol. 2021;31(9):639–44. https://doi.org/10.1089/cap.2021.0011 .
doi: 10.1089/cap.2021.0011
pubmed: 34339282
Wardle J, Waller J, Rapoport L. Body dissatisfaction and binge eating in obese women: the role of restraint and depression. Obes Res. 2001;9(12):778–87.
doi: 10.1038/oby.2001.107
pubmed: 11743062
Lasikiewicz N, Myrissa K, Hoyland A, Lawton C. Psychological benefits of weight loss following behavioural and/or dietary weight loss interventions. A systematic research review. Appetite. 2014;72:123–37.
doi: 10.1016/j.appet.2013.09.017
pubmed: 24075862
Alimoradi Z, Golboni F, Griffiths MD, Broström A, Lin C-Y, Pakpour AH. Weight-related stigma and psychological distress: a systematic review and meta-analysis. Clin Nutr. 2020;39(7):2001–13.
doi: 10.1016/j.clnu.2019.10.016
pubmed: 31732288
Dunlop BW, McCabe B, Eudicone JM, Sheehan JJ, Baker RA. How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. Hum Psychopharmacol Clin Exp. 2014;29(6):528–36.
doi: 10.1002/hup.2428
Zimmerman M, Walsh E, Friedman M, Boerescu DA, Attiullah N. Are self-report scales as effective as clinician rating scales in measuring treatment response in routine clinical practice? J Affect Disord. 2018;225:449–52.
doi: 10.1016/j.jad.2017.08.024
pubmed: 28858659
Cuijpers P, Li J, Hofmann SG, Andersson G. Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. Clin Psychol Rev. 2010;30(6):768–78.
doi: 10.1016/j.cpr.2010.06.001
pubmed: 20619943